首次高敏肌钙蛋白T测量改善急诊诊疗(ICare-FirsT):实现早期排除并缩短留观时间——一项诊断性与观察性研究
该研究分两阶段:第一阶段用高保真研究数据开发并评估一种包含单次hs-cTnT分层的新型路径,低风险阈值为hs-cTnT<5 ng/L;第二阶段在多家急诊科审计单次Roche hs-cTnT策略的实施。第一阶段推导路径在症状发作≥3小时、hs-cTnT<5 ng/L、心电图无缺血表现且急诊胸痛评估评分<21时,16.3%患者为低风险。第二阶段六家医院中,对照组10912例,实施单次检测后13997例;未调整的急诊留观时间平均缩短1.6%(95%CI 0.4%至2.9%),调整就诊量增加后为8.5%(95%CI 7.7%至9.3%)。结论认为单次hs-cTnT<5 ng/L作为临床路径组分可小幅但有意义地缩短急诊平均留观时间。
要点
- 低风险判定需同时满足:症状发作≥3小时抽血、hs-cTnT<5 ng/L、心电图无缺血表现、急诊胸痛评估评分<21。
- 第一阶段推导路径中,满足上述条件者为低风险,占16.3%。
- 第二阶段六家医院对照组10912例,实施单次hs-cTnT后13997例。
- 未调整的急诊留观时间平均缩短1.6%(95%CI 0.4%至2.9%),调整就诊量增加后缩短8.5%(95%CI 7.7%至9.3%)。
- 安全性指标为30天内心肌梗死或非已知非心源性死亡(MACE30)。
适用人群与场景
- 急诊科评估疑似心肌梗死的患者。
- 第一阶段路径低风险判定要求症状发作至抽血时间≥3小时。
诊断标准与关键阈值
- 低风险阈值:hs-cTnT<5 ng/L。
- 低风险需同时满足:单次抽血距症状发作≥3小时、hs-cTnT<5 ng/L、心电图无缺血表现、急诊胸痛评估评分<21。
研究设计与关键结果
- 研究分两阶段:第一阶段用高保真研究数据开发并评估包含单次hs-cTnT分层的新型路径;第二阶段在多家急诊科审计单次Roche hs-cTnT策略的实施。
- 第一阶段:推导路径在满足单次抽血距症状发作≥3小时、hs-cTnT<5 ng/L、心电图无缺血表现、急诊胸痛评估评分<21时,16.3%为低风险。
- 第二阶段:六家医院对照组10912例,实施单次hs-cTnT后13997例。
- 未调整的急诊留观时间平均缩短1.6%(95%CI 0.4%至2.9%);调整就诊量增加后缩短8.5%(95%CI 7.7%至9.3%)。
- 安全性指标为30天内心肌梗死或非已知非心源性死亡(MACE30)。
证据类型、等级与局限
- 诊断性与观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在临床路径中纳入单次hs-cTnT<5 ng/L作为分层组分,可使急诊平均留观时间小幅但有意义地缩短。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pathways incorporating clinical risk assessment, ECG and serial troponin measurements for the assessment of patients with possible myocardial infarction (MI) in the ED are standard practice. Incorporating a single troponin test to stratify to low risk of MI using a baseline measurement of cardiac troponin (cTn) with a high-sensitivity T assay (hs-cTnT) is recommended. We aimed to implement a pathway incorporating a single-test component and measure the impact on length of stay (LOS).
METHODS: There were two study phases: (1) Development and performance assessment of a novel pathway incorporating a single-test hs-cTnT stratification using high-fidelity research data, (2) An audit of the implementation of a single-test Roche hs-cTnT strategy within multiple EDs. The low-risk threshold used for hs-cTnT was 5 ng/L. The safety metric was MI or death not known to be non-cardiac within 30 days (MACE30).
RESULTS: Phase I: The derived pathway had 16.3% low risk after one blood draw ≥3 hours from symptom onset with hs-cTnT <5 ng/L, non-ischaemic ECG and ED Assessment of Chest pain Score <21.
PHASE II: In six hospitals, there were 10 912 patients in the control arm and 13 997 after implementation of single-test hs-cTnT. The unadjusted estimated mean reduction in LOS after intervention was 1.6% (95% CI 0.4% to 2.9%). After adjustment accounting for increased presentations, this was 8.5% (95% CI 7.7% to 9.3%).
CONCLUSIONS: Within clinical pathways, a single test with a result from an hs-cTnT of <5 ng/L as a component resulted in a small, but meaningful, reduction in mean ED LOS.
参考来源
- Pickering JW, Joyce L, Devlin G, et al. Improving Care with the First measurement of high-sensitivity troponin T (ICare-FirsT) to enable early rule out and reduce length of stay: a diagnostic and observational study. Emerg Med J. 2025. PMID: 40500120. doi:10.1136/emermed-2024-214754
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。